An overview of incretin clinical trials

Journal of Family Practice

Volumn 57, Issue 9 SUPPL., 2008, Pages

  Garber, Alan J ^a   Spann, Stephen J ^b  

^a NOVO NORDISK A S   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DIET RESTRICTION; DIET THERAPY; DIZZINESS; EXERCISE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE CONTUSION; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; WEIGHT REDUCTION;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; TREATMENT OUTCOME;

EID: 51949116060     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Byetta [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2008.
2. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585-3596.
3. Januvia [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2007.
4. Brodows R, Milton D, Ridge TD, et al. Exenatide monotherapy improves glycemic control and is well tolerated over 24 weeks in drug-naive patients with type 2 diabetes. Presented at: American Diabetes Association 68m Scientific Session; June 6-10, 2008; San Francisco, CA.
5. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients wim type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
6. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients wim type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
7. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
8. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447.
9. Corner A, Bunck MC, Diamant M, et al. Beta cell function and glycaemic control following one year exenatide therapy, and after 12 week wash-out, in patients with type 2 diabetes. Presented at : European Association for the Study of Diabetes; September 7-11, 2008; Rome, Italy.
10. Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477-485.
11. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-1493.
12. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
13. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195-202.
14. Vilsboll T, Zdravkovic M, Le Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients wim type 2 diabetes. Diabetes Care. 2007;30:1608-1610.
15. Harder H, Nielsen L, Tu DT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915-1921.
16. Mari A, Degn K, Brock B, et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 2007;30:2032-2033.
17. Garber A, Henry R, Ratner R, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with glimepiride: All as monotherapy in type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
18. Nauck MA, Frid A, Hermansen K, et al. Liraglutide, a once-daily human GLP-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin. Presented at; American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
19. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
20. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: All as add-on to metformin and a sulfonylurea in type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
21. Zinman B, Gerich J, Buse J, et al. Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: A randomized, double-blind, placebo-controlled trial. Presented at: European Association for the Study of Diabetes; September 7-11, 2008; Rome, Italy.
22. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335-1342.
23. Matthews D, Marre M, Le-Thi TD, et al. Liraglutide, a once-daily human GLP-1 analog, significantly improves beta-cell function in subjects with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
24. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008;25:152-156.
25. Jendle J, Nauck MA, Matthews D, et al. Liraglutide, a once-daily human GLP-1 analog, reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steatosis compared with glimepiride when added to metformin in subjects with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
26. Colagiuri S, Frid A, Zdravkovic M, et al. The once-daily human GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
27. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-2571.
28. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-2637.
29. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643.
30. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-1568.
31. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61:171-180.
32. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab. 2008;10(suppl 1):43-55.
33. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132-138.
34. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217-223.
35. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890-895.
36. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10:82-90.
37. Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880.
38. Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175-185.
39. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9:166-174.
40. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148-1155.
41. Novartis faces delay rolling out Galvus. http://www.fiercebiotech.com/ story/novartis-faces-delay-rolling-out-galvus/2007-11-06. Accessed June 25, 2008.
42. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30:499-512.
43. DeFronzo R, Fleck P, Wilson C, et al. Alogliptin monotherapy improves glycemic control in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
44. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:376-386.
45. Rosenstock J, Aguilar-Salinas CA, Klein E, et al. Once-daily saxagliptin monotherapy improves glycemic control in drug-naive patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session, June 6-10, 2008, San Francisco, CA.
46. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-267.
47. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, onglycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med. 2005;22:1016-1023.
48. Pratley R, Kipnes M, Fleck P, et al. Alogliptin added to sulfonylurea therapy in patients with type 2 diabetes reduces HbA1c without increasing hypoglycemia. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
49. Pratley R, Reusch J, Fleck P, et al. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
50. Nauck M, Ellis G, Fleck P, et al. Efficacy and safety of alogliptin added to metformin therapy in patients with type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.